Tecan sells off REMP sample management unit

Tecan has announced the sale of its sample management business unit REMP as part of the company’s strategy to focus its growth on the life science sector.

The firm has agreed a deal with Nexus Biosystems which will see the latter company acquire all activities of REMP in a deal valued at 12 million Swiss francs (7.5 million pounds).

Under the terms of the deal, which is expected to close within the next two months, Tecan will be entitled to collect payments based on REMP product sales until the end of 2012.

Thomas Bachmann, chief executive officer of Tecan, expressed confidence that Nexus Biosystems is well-placed to maintain the value of the REMP brand and business.

He added: “At Tecan, we will increasingly focus resources on growth projects in our life sciences core markets and actively expand our end-customer business and our original equipment manufacturer activities.”

Last month, Tecan agreed a deal to supply pharmaceutical company Novartis with instruments to be used as part of a new blood screening portfolio.